

Research article

Open Access

## Antimalarial activity of the anticancer and proteasome inhibitor bortezomib and its analog ZL<sub>3</sub>B

Jennifer M Reynolds\*, Kamal El Bissati\*, Jens Brandenburg, Arthur Günzl and Choukri Ben Mamoun\*

Address: Department of Genetics and Developmental Biology, University of Connecticut Health Center, 263 Farmington Ave, Farmington, CT 06030-3301, USA

Email: Jennifer M Reynolds - jreynolds@student.uhc.edu; Kamal El Bissati - kelbissa@aecom.yu.edu;

Jens Brandenburg - jbrandenburg@uchc.edu; Arthur Günzl - gunzl@uchc.edu; Choukri Ben Mamoun\* - choukri@up.uhc.edu

\* Corresponding author

Published: 23 October 2007

Received: 10 July 2007

BMC Clinical Pharmacology 2007, 7:13 doi:10.1186/1472-6904-7-13

Accepted: 23 October 2007

This article is available from: <http://www.biomedcentral.com/1472-6904/7/13>

© 2007 Reynolds et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### Abstract

**Background:** The high rate of mortality due to malaria and the worldwide distribution of parasite resistance to the commonly used antimalarial drugs chloroquine and pyrimethamine emphasize the urgent need for the development of new antimalarial drugs. An alternative approach to the long and uncertain process of designing and developing new compounds is to identify among the armamentarium of drugs already approved for clinical treatment of various human diseases those that may have strong antimalarial activity.

**Methods:** Proteasome inhibitor bortezomib (Velcade™: [(1R)-3-methyl-1-[[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl) amino]propyl]amino]butyl] boronic acid), which has been approved for treatment of patients with multiple myeloma, and a second boronate analog Z-Leu-Leu-Leu-B(OH)<sub>2</sub> (ZL<sub>3</sub>B), were tested against four different strains of *P. falciparum* (3D7, HB3, W2 and Dd2) that are either sensitive or have different levels of resistance to the antimalarial drugs pyrimethamine and chloroquine.

**Results:** Bortezomib and ZL<sub>3</sub>B are equally effective against drug-sensitive and -resistant parasites and block intraerythrocytic development prior to DNA synthesis, but have no effect on parasite egress or invasion.

**Conclusion:** The identification of bortezomib and its analog as potent antimalarial drugs will set the stage for the advancement of this class of compounds, either alone or in combination therapy, for treatment of malaria, and emphasize the need for large-scale screens to identify new antimalarials within the library of clinically approved compounds.

### Background

Malaria is caused by intraerythrocytic protozoan parasites of the genus *Plasmodium*. It is responsible for more than 300 million clinical cases and over 2 million deaths annually [1]. *Plasmodium falciparum*, the organism that causes

the most lethal form of the disease, is becoming increasingly resistant to almost all available drugs in the antimalarial armamentarium [1]. New chemotherapeutic strategies are therefore urgently needed to combat this disease.

During its intraerythrocytic life cycle, a single *P. falciparum* parasite undergoes multiple morphological and physiological changes and multiplies to produce up to 36 new daughter parasites in ~48 hours. Large-scale genomic and proteomic analyses revealed a coordinated program of gene and protein expression during parasite intraerythrocytic life cycle [2-7]. The first phase of this program occurs during parasite transition from ring to trophozoite stage and is marked by the induction of expression of enzymes required for biosynthesis of proteins and membranes, nutrient acquisition, and degradation of the host cytoplasm. The second phase occurs during transition from trophozoite to early schizont and is manifested by the induction of expression of enzymes required for biosynthesis of ribonucleotides and deoxyribonucleotides and for DNA replication. The third phase occurs during parasite schizogony and is marked by the induction of subunits of the proteasome. The last phase of this program occurs during late schizogony and immediately after invasion and becomes evident by the expression of specific proteins required for host cell invasion [2]. The rise and fall of expression of subsets of proteins during specific stages of parasite intraerythrocytic life cycle suggest a coordinated control of protein turnover during parasite development. In eukaryotes, such regulation is controlled by the proteasome.

Proteasomes are multicatalytic protease complexes whose principle task is the selective degradation of proteins within the cell. Although a fully intact proteasome has not been isolated from *P. falciparum*, the sequencing of this organism revealed a complete set of ORFs encoding homologs of eukaryotic subunits of the proteasome [8-10]. The expression of seven  $\alpha$  and six  $\beta$  subunits of the 20S particle and 16 subunits of the 19S regulatory particle of the putative *P. falciparum* proteasome suggest an important role for this multicatalytic complex in parasite intraerythrocytic cycle. Interestingly, this expression peaks during parasite transition from developmental, structural and metabolic functions to more specialized functions important for the generation of new daughter parasites capable of completing the cycle and invading new host cells [5,6]. This suggests that the parasite proteasome could play an important role in protein turnover and parasite replication. Accordingly, the proteasome inhibitor lactacystin was found to inhibit erythrocytic schizogony of *P. falciparum* prior, but not subsequent, to DNA synthesis and parasite multiplication [11].

Several studies have highlighted the importance of proteasome inhibition as a possible approach for the treatment of cancer and parasitic diseases [11-13]. Lindenthal and colleagues showed that the boronate analog MLN-273 blocks the exoerythrocytic development of *P. berghei* and the intraerythrocytic development of *P. falciparum* [12].

Here we provide data indicating that the proteasome inhibitor and analog of MLN-273, bortezomib (Velcade™: [(1R)-3-methyl-1-[[[(2S)-1-oxo-3-phenyl-2-[(pyrazinyl-carbonyl) amino]propyl]amino]butyl] boronic acid), which has been approved for treatment of patients with multiple myeloma, and a second boronate analog Z-Leu-Leu-Leu-B(OH)<sub>2</sub> (ZL<sub>3</sub>B), which was found to be highly toxic to trypanosomatid parasites (IC<sub>50</sub> of 0.32 nM in culture; [14]) are potent inhibitors of *P. falciparum*.

Bortezomib was the first proteasome inhibitor shown to have anti-cancer activity and to induce a marked and durable response in patients with multiple myeloma in clinical trials [15]. We have tested bortezomib and ZL<sub>3</sub>B in different strains of *P. falciparum* including strains that are resistant to pyrimethamine and chloroquine. We found that both compounds are equally effective against drug-sensitive and -resistant parasites with inhibitory concentrations in the low nanomolar range. The compounds block intraerythrocytic development prior to DNA synthesis, but had no effect on parasite egress or invasion.

## Methods

### Strains

The clones 3D7, HB3, Dd2, and W2 of *P. falciparum* used in this study were obtained from the Malaria Research and Reference Reagent Resource Center (MR4).

### Cell Culture and Materials

Parasites were cultured by the method of Trager and Jensen [16] by using a gas mixture of 3% O<sub>2</sub>, 3% CO<sub>2</sub>, and 94% N<sub>2</sub>. RPMI medium 1640 was supplemented with 30 mg/liter hypoxanthine (Sigma), 25 mM Hepes (Sigma), 0.225% NaHCO<sub>3</sub> (Sigma), 0.5% Albumax I (Life Technologies, Grand Island, NY), and 10 µg/ml gentamycin (Life Technologies). Bortezomib was purchased from the University of Connecticut Health Center Pharmacy. ZL<sub>3</sub>B was purchased from Boston Biochemical Inc. (Cat# I-120). Parasite synchronization was obtained with three successive 5% sorbitol treatments [17]. To determine visually the stage of the parasite life cycle, fixed smears of the *P. falciparum*-infected erythrocytes were stained with Giemsa stain and analyzed by bright-field microscopy.

### Hypoxanthine incorporation assay

The susceptibility of parasites to different compounds was assessed by tritiated hypoxanthine uptake as described by Desjardins and colleagues [18]. Briefly, infected erythrocytes (2% hematocrit, 3% rings) were washed and incubated with the appropriate drugs at the listed concentrations in hypoxanthine-free media for 48 hours. 200 µL of the mixture was then added to a 96 well plate with <sup>3</sup>H-hypoxanthine at a concentration of 0.5 µCi/well. Following an incubation of 24 hours, the cells were washed on an ultrafilter and radioactivity was counted


using a scintillation counter.  $IC_{50}$ 's are represented in nM. Values are means  $\pm$  standard deviation of three independent experiments each performed in triplicate. These experiments were performed at least three times with similar results.

## Results and Discussion

### ZL<sub>3</sub>B and bortezomib inhibit the *P. falciparum* intraerythrocytic cycle

The cell permeable peptide boronate Z-Leu-Leu-Leu-B(OH)<sub>2</sub> (ZL<sub>3</sub>B) (Fig. 1A) is a specific and potent proteasome inhibitor that blocks the growth of the bloodstream

form of the protozoan parasite *Trypanosoma brucei* with a 50% inhibitory concentration ( $IC_{50}$ ) of 0.32 nM in culture [14]. In order to examine the antimalarial activity of ZL<sub>3</sub>B, we have tested the effect of increasing concentrations of this compound up to 200 nM on the intraerythrocytic life cycle of *P. falciparum* in culture by following the incorporation of radiolabeled hypoxanthine into parasite nucleic acids. The study was performed with four different strains of *P. falciparum* (3D7, HB3, W2 and Dd2) that are either sensitive or have different levels of resistance to the antimalarial drugs pyrimethamine and chloroquine (Fig. 1C-F and Table 1). ZL<sub>3</sub>B was found to inhibit parasite



**Figure 1**

Structures of ZL<sub>3</sub>B (A) and bortezomib (B). Inhibition of 3D7 (closed squares), HB3 (open squares), W2 (open circles), and Dd2 (open triangles) parasite clones as a function of ZL<sub>3</sub>B (C), bortezomib (D), pyrimethamine (E) and chloroquine (F) concentrations. The clones of *P. falciparum* used in this study were obtained from the Malaria Research and Reference Reagent Resource Center (MR4).  $IC_{50}$ 's are represented in nM. Values are means  $\pm$  standard deviation of three independent experiments each performed in triplicate.


proliferation with an IC<sub>50</sub> values between 34 and 45 nM. Due to the strong antimalarial activity of ZL<sub>3</sub>B, we speculated that the ZL<sub>3</sub>B analog and clinically approved peptide boronate, bortezomib (Fig. 1B) might have a similar antimalarial activity. Bortezomib is a boronic acid dipeptide and a reversible inhibitor of the chymotrypsin-like activity of the 20S proteasome [15]. It strongly and selectively inhibits the proteasome, has substantial cytotoxicity against a broad range of human tumor cells and has shown excellent anti-tumour activity in preclinical and clinical trials [15]. Bortezomib was approved by the U.S. Food and Drug Administration and the European commission for the treatment of advanced multiple myeloma, and more recently, it received a fast track status for relapsed and refractory mantle cell lymphoma [13]. We first analyzed the antimalarial activity of bortezomib by using the hypoxanthine assay and found that the drug inhibited proliferation of *P. falciparum* 3D7, HB3, W2 and Dd2 strains with IC<sub>50</sub> values ranging between 31 and 43 nM (Fig. 1D and Table 1). As a control, we confirmed the IC<sub>50</sub> of chloroquine and pyrimethamine in the four strains (Fig. 1E and 1F, and Table 1). As expected, strain 3D7 was sensitive to both compounds with IC<sub>50</sub> of 6 ± 0.2 and 5 ± 1.1 nM, respectively; strain HB3 was sensitive to chloroquine (IC<sub>50</sub>: 8 ± 1.4 nM) and resistant to pyrimethamine (IC<sub>50</sub>: 500 ± 45 nM); strain W2 was moderately resistant to chloroquine (IC<sub>50</sub>: 90 ± 3.7 nM) and highly resistant to pyrimethamine (IC<sub>50</sub>: 1.5 ± 0.006 μM), and Dd2 was highly resistant to both chloroquine (IC<sub>50</sub>: 300 ± 21 nM) and pyrimethamine (IC<sub>50</sub>: 2.5 ± 0.097 μM). To further confirm the inhibitory effects of bortezomib and ZL<sub>3</sub>B on *P. falciparum* growth, we employed the pLDH colorimetric assay, which measures the production of parasite specific lactate dehydrogenase activity [19-21]. Consistent with the results of the hypoxanthine incorporation assay, both compounds were found to inhibit equally well chloroquine- and pyrimethamine- sensitive and resistant strains (not shown). Noteworthy, these studies were also consistent with the finding that another boronic derivative, MLN-273, inhibits the intraerythrocytic development of *P. falciparum* [12].

**Table 1: 50% Inhibitory concentrations IC<sub>50</sub> (nM) of ZL<sub>3</sub>B, bortezomib, chloroquine and pyrimethamine in *P. falciparum* strains**

	3D7	HB3	W2	Dd2
<b>ZL<sub>3</sub>B</b>	40 ± 12	45 ± 5.8	34 ± 3.9	40 ± 11.1
<b>Bortezomib</b>	31 ± 1.8	31 ± 2.7	43 ± 4	37 ± 5.1
<b>Chloroquine</b>	6 ± 0.2	8 ± 1.4	90 ± 3.7	300 ± 21
<b>Pyrimethamine</b>	5 ± 1.1	500 ± 45	1500 ± 5.8	2500 ± 97

**Bortezomib and ZL<sub>3</sub>B antimalarial activities occur prior to DNA synthesis**

To determine the developmental stage during which bortezomib and ZL<sub>3</sub>B exert their antimalarial effects, *P. falciparum* cultures were synchronized and the proteasome inhibitors were added to the culture medium at different times following parasite invasion and a final concentration of 100 nM. Culture samples were collected every 6 hours and parasite intraerythrocytic developmental progression was monitored by Giemsa staining and light microscopic analysis (Fig. 2A). As a control, an untreated culture of *P. falciparum*-infected erythrocytes was monitored. In the absence of bortezomib or ZL<sub>3</sub>B, the parasite displayed a normal cycle progression from rings to trophozoites, trophozoites to schizonts and schizonts to rings in approximately 44 hours (Fig. 2A). Addition of bortezomib or ZL<sub>3</sub>B during the ring (8, 16 h post-invasion) or early trophozoite (24 h post-invasion) stages resulted in a complete blockage of developmental progression and subsequent death of the parasites. Treatment with these compounds during the late trophozoite stage (32 h post-invasion) only partially blocked parasite progression (Fig. 2B). On the other hand, treatment during the schizont stage (40 h post-invasion) had no effect on parasite progression (Fig. 2A). This stage-specific inhibitory effect of bortezomib and ZL<sub>3</sub>B was quantified by



**Figure 2**  
**(A)** Stage specific inhibition of *P. falciparum* (3D7) parasite by ZL<sub>3</sub>B and bortezomib. Highly synchronized cultures of the parasites were grown in the absence or presence of 100 nM of ZL<sub>3</sub>B or bortezomib, stained by Giemsa stain, and analyzed by light microscopy. **(B)** Estimated number of daughter rings formed 48 h following parasite (3D7) invasion of host erythrocytes in the absence (U) or presence of ZL<sub>3</sub>B (Z) or bortezomib (B). Drugs were applied at 8, 16, 24, 32, 40 and 48 h following parasite invasion.

counting the number of rings that developed 48 hours post-invasion in the absence or presence of the compounds. Consistent with the previous analysis, no rings could be detected from cultures treated with bortezomib or ZL<sub>3</sub>B 8, 16 or 24 h post-invasion. In contrast, treatment with these compounds 32 h post-invasion reduced the number of rings in comparison to untreated parasites by 40% only (Fig. 2B) and treatment 40 h post-invasion was completely ineffective (not shown). Together these data suggest that these compounds inhibit parasite development and multiplication and have a lesser effect on the release of merozoites from the infected erythrocytes or on the invasion of new red blood cells by the released merozoites. Although a direct effect of these compounds on the proteasome has not been investigated, our data along with the known mode of action of these compounds in other cell lines suggest an important role for the *P. falciparum* proteasome in parasite development and DNA synthesis.

The recommended adult dose of bortezomib for treatment of myeloma is 1.3 mg/m<sup>2</sup>; and in children the compound is used at a dose of 1.2 mg/m<sup>2</sup> [22-24]. The mean peak plasma concentration (C<sub>max</sub>) determined 5 min after drug administration at doses between 1.3 and 1.7 mg/m<sup>2</sup> was 63 ± 16 ng/ml and the mean area under the concentration-time curve extrapolated to infinity (AUC<sub>inf</sub>) was 27 h ng/ml [23]. These values are 2 to 4-fold the IC<sub>50</sub> observed with bortezomib in *P. falciparum*. *In vivo* studies to determine the dose and tolerability of this compound for treatment of malaria are warranted.

## Conclusion

Our studies demonstrate that two boronates, ZL<sub>3</sub>B and its clinically-approved analog bortezomib, are potent inhibitors of the intraerythrocytic cycle of both drug-sensitive and resistant *P. falciparum* strains. These findings will set the stage for the evaluation of this new class of compounds for treatment and/or prophylaxis of *falciparum* malaria. Furthermore, our studies set the stage for large-scale screens to identify new antimalarials among clinically approved drugs. This approach could shorten the lengthy and expensive process of designing, developing and testing the potency, efficacy and safety of new drugs.

## Competing interests

The author(s) declare that they have no competing interests.

## Authors' contributions

JMR and KEB carried out all the experiments presented in this work and helped in the writing and revision of the manuscript. JB helped in the design of the study and interpretation of the data. AG and CBM conceived and designed the project, helped in the analysis and interpre-

tation of the data, and the writing and revision of the manuscript. All authors read and approved the final manuscript.

## Acknowledgements

We are grateful to Harriett Zawistowski (General Clinical Research Center, University of Connecticut Health Center) for technical help. We thank Dr. David Sullivan for technical assistance. This research was supported by NIH and DOD grants AI51507, AI58962, PR033005 and BWWF award I006267 to CBM and NIH grant AI059377 to AG. UCHC General Clinical Research Center is supported by NIH Grant M01RR06192. CBM is a recipient of the Burroughs Wellcome Award, Investigators of Pathogenesis of Infectious Disease.

## References

1. **WHO Expert Committee on Malaria.** *World Health Organ Tech Rep Ser* 2000, **892(i-v)**:1-74.
2. Ben Mamoun C, Gluzman IY, Hott C, MacMillan SK, Amarakone AS, Anderson DL, Carlton JM, Dame JB, Chakrabarti D, Martin RK, Brownstein BH, Goldberg DE: **Co-ordinated programme of gene expression during asexual intraerythrocytic development of the human malaria parasite *Plasmodium falciparum* revealed by microarray analysis.** *Mol Microbiol* 2001, **39(1)**:26-36.
3. Bozdech Z, Zhu J, Joachimiak MP, Cohen FE, Pulliam B, DeRisi JL: **Expression profiling of the schizont and trophozoite stages of *Plasmodium falciparum* with a long-oligonucleotide microarray.** *Genome Biol* 2003, **4(2)**:R9.
4. Florens L, Washburn MP, Raine JD, Anthony RM, Grainger M, Haynes JD, Moch JK, Muster N, Sacci JB, Tabb DL, Witney AA, Wolters D, Wu Y, Gardner MJ, Holder AA, Sinden RE, Yates JR, Carucci DJ: **A proteomic view of the *Plasmodium falciparum* life cycle.** *Nature* 2002, **419(6906)**:520-526.
5. Le Roch KG, Johnson JR, Florens L, Zhou Y, Santrosyan A, Grainger M, Yan SF, Williamson KC, Holder AA, Carucci DJ, et al.: **Global analysis of transcript and protein levels across the *Plasmodium falciparum* life cycle.** *Genome Res* 2004, **14(11)**:2308-2318.
6. Le Roch KG, Zhou Y, Blair PL, Grainger M, Moch JK, Haynes JD, De La Vega P, Holder AA, Batalov S, Carucci DJ, Winzeler EA: **Discovery of gene function by expression profiling of the malaria parasite life cycle.** *Science* 2003, **301(5639)**:1503-1508.
7. Young JA, Fivelman QL, Blair PL, de la Vega P, Le Roch KG, Zhou Y, Carucci DJ, Baker DA, Winzeler EA: **The *Plasmodium falciparum* sexual development transcriptome: a microarray analysis using ontology-based pattern identification.** *Mol Biochem Parasitol* 2005, **143(1)**:67-79.
8. Gille C, Goede A, Schloetelburg C, Preissner R, Kloetzel PM, Gobel UB, Frommel C: **A comprehensive view on proteasomal sequences: implications for the evolution of the proteasome.** *J Mol Biol* 2003, **326(5)**:1437-1448.
9. Li GD, Li JL, Mugthim M, Ward SA: **Molecular cloning of a gene encoding a 20S proteasome beta subunit from *Plasmodium falciparum*.** *Int J Parasitol* 2000, **30(6)**:729-733.
10. Paugam A, Bulteau AL, Dupouy-Camet J, Creuzet C, Friguet B: **Characterization and role of protozoan parasite proteasomes.** *Trends Parasitol* 2003, **19(2)**:55-59.
11. Gantt SM, Myung JM, Briones MR, Li WD, Corey EJ, Omura S, Nussenzweig V, Sillis P: **Proteasome inhibitors block development of *Plasmodium* spp.** *Antimicrob Agents Chemother* 1998, **42(10)**:2731-2738.
12. Lindenthal C, Weich N, Chia YS, Heussler V, Klinkert MQ: **The proteasome inhibitor MLN-273 blocks exoerythrocytic and erythrocytic development of *Plasmodium* parasites.** *Parasitology* 2005, **131(Pt 1)**:37-44.
13. Nencioni A, Grunebach F, Patrone F, Ballestrero A, Brossart P: **Proteasome inhibitors: antitumor effects and beyond.** *Leukemia* 2007, **21(1)**:30-36.
14. Nkemngu NJ, Rosenkranz V, Wink M, Steverding D: **Antitrypanosomal activities of proteasome inhibitors.** *Antimicrob Agents Chemother* 2002, **46(6)**:2038-2040.

15. Roccaro AM, Hideshima T, Richardson PG, Russo D, Ribatti D, Vacca A, Dammacco F, Anderson KC: **Bortezomib as an antitumor agent.** *Curr Pharm Biotechnol* 2006, **7(6)**:441-448.
16. Trager W, Jensen JB: **Human malaria parasites in continuous culture.** *Science* 1976, **193(4254)**:673-675.
17. Lambros C, Vanderberg JP: **Synchronization of *Plasmodium falciparum* erythrocytic stages in culture.** *J Parasitol* 1979, **65(3)**:418-420.
18. Desjardins RE, Canfield CJ, Haynes JD, Chulay JD: **Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique.** *Antimicrob Agents Chemother* 1979, **16(6)**:710-718.
19. Makler MT, Hinrichs DJ: **Measurement of the lactate dehydrogenase activity of *Plasmodium falciparum* as an assessment of parasitemia.** *Am J Trop Med Hyg* 1993, **48(2)**:205-210.
20. Makler MT, Piper RC, Milhous WK: **Lactate dehydrogenase and the diagnosis of malaria.** *Parasitol Today* 1998, **14(9)**:376-377.
21. Makler MT, Ries JM, Williams JA, Bancroft JE, Piper RC, Gibbins BL, Hinrichs DJ: **Parasite lactate dehydrogenase as an assay for *Plasmodium falciparum* drug sensitivity.** *Am J Trop Med Hyg* 1993, **48(6)**:739-741.
22. Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemester F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM: **Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.** *J Clin Oncol* 2005, **23(4)**:667-675.
23. Horton TM, Pati D, Plon SE, Thompson PA, Bomgaars LR, Adamson PC, Ingle AM, Wright J, Brockman AH, Paton M, Blaney SM: **A phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study.** *Clin Cancer Res* 2007, **13(5)**:1516-1522.
24. O'Connor OA, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, Straus D, Portlock C, Hamlin P, Choi E, Dumetrescu O, Esseltine D, Trehu E, Adams J, Schenkein D, Zelenetz AD: **Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.** *J Clin Oncol* 2005, **23(4)**:676-684.

### Pre-publication history

The pre-publication history for this paper can be accessed here:

<http://www.biomedcentral.com/1472-6904/7/13/prepub>

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
[http://www.biomedcentral.com/info/publishing\\_adv.asp](http://www.biomedcentral.com/info/publishing_adv.asp)

